Technology

Big data has proven to be a valuable business asset, but using it to gain competitive advantage requires the right combination of strategy, technology and execution, write Mahmood Majeed, Vickye Jain, and Sandeep Varma.

Multi-channel marketing manager Adi Borovick discusses the implications of compliance for marketers in a world where new technologies being created every day.

In the 21st Century Cures Act, Congress excluded from FDA regulation certain clinical decision support, or CDS, software.

Pharm Exec speaks to Andrew Marr about the implications of the European Union's new IDMP (Identification of Medicinal Products) regulations for the pharma industry.

The digital workplace is defined as a “business strategy to boost employee engagement and agility through a more consumerized work environment”. But what exactly does this mean for life sciences organizations? Michael Woodbridge explains.

It’s no longer sufficient for a pharma to develop better products or even build simple apps. The industry increasingly needs to create sophisticated predictive algorithms to maximize the ability of its products, write Tom Agan and Fred Geyer.

Emil Eifrem examines how life science researchers can uncover new insights using the in-built power of graph technology.

Christopher Rudolf and Adam Sherlock explain how artificial intelligence can transform that challenging scenario through the application of reliable and efficient life sciences web and social listening as an integral part of safety monitoring.

Clinical trial data from completed trials are now beginning to be shared through a variety of channels. While skeptics remain, evidence is growing that this data can lead to practice-changing behavior in patient care.

The absence of pharma brands on social media creates a significant void of reputable healthcare information to aid patients, writes Dawn Lacallade.

Charles Benaiah, CEO of New York's watzan, tells Pharm Exec that the key to effective social media marketing is personalization.

If pharma companies want to hold their own in the current climate, they must embrace rather than resist market change.

While technology is already impacting the pharma industry, automation and the Internet of things (IoT) will intensify over the next two years, and those companies that experiment and embrace it will have a “dramatic and competitive advantage.”

Pharma must develop digital identity strategies for creating seamless, safe and compliant customer journeys, writes Jamie Beckland.

If pharma companies want to hold their own in the current climate, they must embrace rather than resist market change, writes Peter Muller.

Pilot study affirms the value of a standards-based solution for prescription drug traceability-and the need to start now to meet compliance deadlines for the Drug Supply Chain Security Act.

While it is foundational to commercial operations, most European life sciences companies are not getting what they need from their customer data, writes Guillame Roussel.

With big data one of the hot healthcare topics of the moment, we gauge pharma’s response to the hype to see if the industry is poised to take advantage of the promise of advanced analytics.

Jeff R. Livingstone outlines the critical steps necessary to ensure an agile, responsive and streamlined supply chain.

Amid the push for a more intelligent and predictive supply chain, is it imperative for pharma companies to advance with their supply chain digitization strategies now-or is there still time to “wait and see?”

Facing mixed market signals, biotech companies look to rise above the fray in advancing new-wave discoveries to the clinical finish line.

How integrating next-generation sequencing data can advance efforts in immuno-oncology research.

Laurent Fanichet outlines four ways pharma companies can use cognitive search and search-based applications to improve competitiveness.